At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMMX Immix Biopharma, Inc.
Pre-Mkt 02-02 04:37:56 EST
5.83
-0.12
-2.02%
High6.20Low5.75Vol864.76K
Open5.87D1 Closing5.95Amplitude7.64%
Mkt Cap308.73MTradable Cap241.59MTotal Shares52.96M
T/O5.11MT/O Rate2.09%Tradable Shares41.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy
Reuters  ·  01-28
BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy
FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis
Reuters  ·  01-28
FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for Nxc-201
THOMSON REUTERS  ·  01-28
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for Nxc-201
Immix Biopharma Inc: Final Data Expected This Year Followed by Planned Bla Submission
THOMSON REUTERS  ·  01-28
Immix Biopharma Inc: Final Data Expected This Year Followed by Planned Bla Submission
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities
Benzinga_recent_news  ·  01-12
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities
BRIEF-Immix Biopharma To Offer And Sell Up To $750 Million In Securities - SEC Filing
Reuters  ·  01-10
BRIEF-Immix Biopharma To Offer And Sell Up To $750 Million In Securities - SEC Filing
Immix Biopharma files $750M mixed securities shelf
TIPRANKS  ·  01-10
Immix Biopharma files $750M mixed securities shelf
Immix Biopharma Inc - to Offer and Sell up to $750 Mln in Securities - SEC Filing
THOMSON REUTERS  ·  01-10
Immix Biopharma Inc - to Offer and Sell up to $750 Mln in Securities - SEC Filing
Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges
Reuters  ·  01-10
Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges
Immix Biopharma CEO Ilya Rachman Acquires Common Shares
Reuters  ·  2025-12-11
Immix Biopharma CEO Ilya Rachman Acquires Common Shares
Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares
Reuters  ·  2025-12-11
Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares
BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants
Reuters  ·  2025-12-10
BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-12-09
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $12 From $8
THOMSON REUTERS  ·  2025-12-09
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $12 From $8
Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges
Reuters  ·  2025-12-09
Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges
BRIEF-Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share
Reuters  ·  2025-12-08
BRIEF-Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  2025-12-08
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma Inc - Prices Offering of 19.12 Mln Shares at $5.10 per Share
THOMSON REUTERS  ·  2025-12-08
Immix Biopharma Inc - Prices Offering of 19.12 Mln Shares at $5.10 per Share
Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis
Reuters  ·  2025-12-08
Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis
at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis
THOMSON REUTERS  ·  2025-12-08
at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

Introduction

Company Name.
Immix Biopharma, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Issue price:
--